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ABSTRACT 
Background: A renal allograft is the best therapeutic alternative for patients with end stage renal diseases. 
Nonetheless, rejection still represents a great challenge. In order to overcome this issue, therapeutic strategies 
include the combined use of immunosuppressive and anti-inflammatory agents, but they are not exempt from 
complications . Interestingly, the major cause of morbidity and mortality after the first transplanted year are due to 
disorders unrelated directly to immunologic etiology or disease related to immunosuppressive drugs. Objectives: 
The purpose of this study is to determine the side effects in renal transplant Yemeni patients adherence to 
cyclosporine compared to tacrolimus sharing the same adjuvant agents which are mycophenolate mofetil "MMF" 
and prednisone. Subject and methods: This study was carried on 100 kidney transplanted Yemeni patients 
divided into two groups: cyclosporine group (n=50) and tacrolimus group (n=50), each member of these groups 
was visited three times, blood samples was collected for biochemical functions including fasting blood sugar, liver 
enzymes, kidney functions, lipid profiles and white blood cells counts. Body weight and blood pressure had been 
examined; clinical complications were also estimated by a medical records. Results: This study showed that 
serum total and direct bilirubine, gamma glutamyl transferase "GGT" and lipid profiles were elevated in 
cyclosporine group, whereas in tacrolimus group they were within normal range. The incidence of complicated 
events reported as follows: Hairtusim, gum hyperplasia, herpeszoster, coushing face and obesity were obviously 
present in cyclosporine group, while in tacrolimus group diabetes mellitus, hair loss and gastrointestinal tract 
infections were exist. Conclusion: This study found that a tacrolimus-based treatment was significantly better than 
an immunosuppressive regimen based on cyclosporine due to the generally less side effects associated with 
tacrolimus, despite its effect on increasing diabetes among kidney transplant patients.  
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INTRODUCTION 
Kidney transplantation is the preferred treatment for most patients with end-stage kidney disease (ESRD)l.  Kidney 
transplantation for patients with ESRD can improve endurance and quality of life, and lower the cost of health care. Currently, 
the 1-year patient survival rates and graft survival rates are 94% and 82%, respectively2,3. The incidence of ESRD in Yemen is 
120 cases per million annually, which is comparable to the incidents reported in other posts in the same region4,5,6. In Yemen, 
the kidney transplant program began intermittently since 1998. However, there has been a well-established program that has 
been running regularly since the beginning of 2005 in the Urology and Nephrology Center at Al-Thawra Modern General 
Hospital, Sana'a7.  Despite significant advances in the field of kidney transplantation, long-term graft survival has not 
increased significantly due to the continuing effect of immunosuppressive and infectious disease on transplant recipients 8,9. 
Several immunosuppressive agents are currently in use in protective immunity in kidney transplant recipients. Commonly used 
oral immunosuppressive agents fall into three categories: calcineurin inhibitors (cyclosporine and tacrolimus), antiproliferative 
agents (azathioprine and mycophenolate mofetil) and steroids (prednisone). The combined use of one agent in each class is 
known as triple therapy, and it is the standard regimen for early to mid-term immunosuppression after transplantation. This 
provides broad immunosuppression based on the different mechanisms of action for each group 10. Medicines are not without 
challenges and risks. Recipients need to continue to take immunosuppressive drugs for the rest of their lives to prevent 
allograft rejection, and this trade in morbidity and mortality from organ failure to risks of infection and cancer. In addition, 
these drugs are likely to contribute to increased mortality from cardiovascular disease, which is the leading cause of premature 
death in kidney transplant recipients 10. Cyclosporine A (CyA) and tacrolimus (TAC), as calcineurin inhibitors, are used at the 
time of transplantation to achieve adequate immunosuppression and to prevent acute episodes of rejection 3. CyA was revealed 
 
 
in 1971, and in 1983, this drug was permitted for the prevention of organ transplant rejection. TAC (Prograf) was discovered 
in the early 1980's and from 1989, and is used to prevent liver transplant rejection. After that, the use of this drug quickly 
developed for transplantation of other organs11. Because of the possibility of different effects in Yemeni patients compared to 
other nationalities, and also that there was no study on this topic in advance in Yemen, so this follow-up study was done with 
the aim of evaluating the differences in kidney transplant patients, who share the same immunosuppressive adjuvants, which 
are mycophenolate mofetil. MMF '+ prednisone but differs in the calcineurin inhibitor, one group used cyclosporine and 
another group used tacrolimus regarding its effect on kidney and liver function, lipid properties, and complete blood cell 
count. Also investigating the possible relationship between the groups cyclosporine and tacrolimus with respect to other 
clinical side effects such as hypertension, diabetes, obesity, and dysmorphic changes. 
SUBJECTS AND METHODS 
This study was conducted at Al-Thawra Hospital and the National Center for Public Health Laboratories in Sana'a on one 
hundred Yemeni patients with kidney transplants ranging in age (14 - 60 years): 59 men and 41 females between September 
2016 to September 2017. They were divided into two groups: (Group A) 50 patients (39 males, 11 females) on a cyclosporine-
based immunosuppressant regimen, (group II) 50 patients (20 males and 30 females) with a tacrolimus-based 
immunosuppressive regimen. All patients were informed of the aim of the study and gave their consent. 
Both drugs were administered in two divided doses and the dose was adjusted according to clinical responses and blood trough 
levels for 12 hours. The whole blood trough level of tacrolimus was maintained between 5-15 ng / ml and cyclosporine 
between 100-200 ng / ml. Doses were tapered based on the concentration of the drug in whole blood and clinical examination.  
Sample processing:  Blood samples were drawn for all measurements in the morning from 8 am to 11 am. Two tubes with 
EDTA one for cyclosporine or tacrolimus and the second for CBC, another plain tube for chemical parameters. Analysis was 
performed on the same day of collection and results were recorded at three-month intervals. The samples were taken for 
analysis of cyclosporine and tacrolimus blood levels, fasting blood sugar, kidney function tests (KFT)including urea and 
creatinine tests, liver functions tests (LFT) included bilurubine total and direct,glotamate oxaloacetate transaminase GOT, 
glutamate pyruvate transaminase GPT,alkaline phosphataes ALK, and gamma glutamate transaminase GGT tests , lipid 
profiles (total cholesterol, high density lipoprotein ,low density lipoprotein and triglyceride) also the complete blood count 
CBC were determined. Blood pressure and body weight were also recorded with an automatic scale. Data from the renal 
recipient records were investigated retrospectively to determine the immunosuppressant complications among the renal 
allograft recipients.  
Ethical consideration:  Ethical approval was obtained from the Ethical Committee of the medical research at Sana'a 
University. Approval was obtained from all participants before recruiting them to the study and after explaining for them the 
aim of the study. 
Statistical analysis: Data of completed questionnaire obtained, and were manipulated using Statistical Package for the Social 
Science version 21.0 software (SPSS version 21.0).  
RESULTS  
The recipient's age, ranged from 14-60 years and their mean age was 32.4 years in both groups. A significant difference was 
only found in recipients aged at > 45 years as in cyclosporine group was 16% while in tacrolimusit it was 8%. Regarding to 
gender 78% male and 22% female have been found in cyclosporine group while in tacrolimus group were 40% male and 60% 
female [Table 1].  Their causes of renal failure was clinically diagnosed as follows: Hypertension (37%), Kidney atrophy 
(14%), Chronic urinary tract infection (14%), Stones (10%), Antibiotic abuse (4%), Hereditary (4%), Diabetes mellitus (3%), 
and (14%) unknown cause [Table 2]. All renal recipients were received a single kidney from a living donors aged between 18-
55 years, in cyclosporine group (46%) of the donors were relatives and (54%) were unrelatives , while in tacrolimus group 
(72%) of the donors were relatives and (41% ) were unrelatives.   Also the drugs levels were similar in both groups; 62% and 
64% of the cyclosporine and tacrolimus respectively were within normal ranges of the trough blood level which is 100-200 
ng/ml for cyclosporine and 5-15 ng/ml for tacrolimus, and 38% in cyclosporine group and 36%in tacrolimus group were have 
 
 
been shifted from their trough blood level [Table 3]. The post transplant means values of sugar, LFT, KFT, and lipid profiles 
are summarized in [Table 4], the significant difference were found in the elevation of total and direct bilirubin, GGT, total 
cholesterol, LDL, HDL, and triglycerides in cyclosporine group while not in tacrolimus group (P<0.0001). No differences in 
the other test biochemical's parameters were detected between the two groups as shown in table 4. There was a significant 
difference in Hb (p<0.0001) and Plts (p<0.023) while no difference had been found in WBCs between the two groups [Table 
5]. The incidence of adverse events reported in Table 6 included: 64% hairtusim, 54% obesity, 16% gum hyperplasia , 22% 
couching face, 10% herpes zoster, 28% herpes simplex, and 2% Kaposi sarcoma were associated with cyclosporine group, 
and this was significant. On the other hand gastrointestinal infection 24%, DM 20%, hair loss 20% ,10% gastritis and had 
been found in tacrolimus group while not in cyclosporine group.12% of cyclosporine group and 8% of tacrolimus group had 
no complications during the follow up time (one year). 
DISCUSSION 
The results of this study showed that the fasting blood sugar levels in both groups were similar and at the top of their normal 
range. Although, diabetes mellitus as a clinical complication is appeared in 20% of tacrolimus group whereas in cyclosporine 
group was only 2%. This is in agreement with the fact that after renal transplantation some 45% of patients may show 
abnormal glucose tolerance and 20–25% may develop diabetes12.  Another study showed that tacrolimus is associated with 
diabetes mellitus, due to the increased concentration of FKBP (FK binding protein) in pancreatic islets relative to cyclophiline 
during drugs metabolism. Morphologic changes in the islets include cytoplasmic swelling, vacuolization, and apoptosis, with 
normal immune-staining for insulin, this effect is dose related and may be exaggerated by concomitant corticosteroid use 
especially prednisone 13. Some previous studies suggested that tacrolimus influences glucose metabolism by reducing 
pancreatic insulin secretion in a dose-dependent manner 14 . Initially, an increased insulin resistance was also reported15, but 
this seems to be the result of the co-administration of steroids 14. Both prednisone and calcineurin – inhibitors provide 
additional risk factors, with tacrolimus conveying an increased risk, as compared to cyclosporine. Corticosteroids have been 
shown to produce peripheral insulin resistance and to cause alteration in pancreatic beta-cell insulin secretion. Cyclosporine 
and tacrolimus also appear to alter peripheral insulin sensitivity and to diminish islet function16. 
   In the current study, the mean serum values of urea and creatinine were at the upper limit of their normal range. This is 
supported by another study, which reported that both cyclosporine and tacrolimus produce a chronic arteriolopathy and 
chronic toxicity with irreversible kidney damage 17 and this elevation indicate a significant, potentially graft-endangering 
event18. The calcineurin inhibitors CsA and FK506 produce a dose –related reversible renal vasoconstriction that particularly 
affects the afferent arteriole, the glomerular capillary ultrafiteration coefficient also decreases .Most of the studies on the 
mechanism of this effect have used cyclosporine rather than tacrolimus19.This have explained why cyclosporine affect on 
kidney function is obvious, as the main adverse effect caused by cyclosporine is nephrotoxicity, the long term use of CsA can 
result in a chronic toxicity associated with irreversible and progressive decrease in renal function and this characterized by 
tubular –interstitial fibrosis and hyaline degenerative changes in the afferent arteriole walls 20, this lead to vasoconstriction that 
causes acute reversible decrease in GFR" glumerular filtration rate " 21. 
Although this study have shown that the blood concentration of urea and creatinine were higher in tacrolimus group (urea: 
7.99± 8.3, creatinine: 116 ± 74.7) than in cyclosporine group (urea: 6.18 ±2.1, creatinine: 113± 32.5) , this is not agreement 
with some studies that indicated tacrolimus and MMF" mycophenolate mofetil " significantly improved kidney function 22 , 
and the serum creatinine concentrations were better in tacrolimus group ,due to MMF 23 .But agreement with a study reported 
that ,the majority of renal transplant patients tolerate long-term cyclosporine therapy without evidence of progressive toxic 
nephropathy 24. 
There was a significant increase in total, direct bilirubin blood levels and gamma glutamyl transpeptidase "GGT" in 
cyclosporine group rather than tacrolimus group .This is in agreement with the study reported that episode of hepatic 
dysfunction typically manifesting as sub clinical, mild, self limiting, and dose-dependant elevations of serum aminotransferase 
levels with mild hyperbilirubinemia may occur in nearly half of all kidney transplant recipients taking cyclosporine and occur 
 
 
less frequently in those taking tacrolimus. No specific hepatic histologic lesion has been described in humans, and the 
hyperbilirubinemia is a reflection of disturbed bile secretion rather than hepatocellular damage, cyclosporine doesn't itself 
produce progressive liver disease; other cause, most frequently one of the viral hepatitis25. Even some studies found that both 
cyclosporine and tacrolimus cause hepatotoxicity and liver dysfunction 26, 27 . 
Lipid profiles including total cholesterol, HDL, LDL, TG were significantly altered with cyclosporine and elevated in 
comparison to tacrolimus group in the current study .This results were similar to those obtained by another studies which 
assessed hyperlipidemia is one of the metabolic a adverse effects of cyclosporine and tacrolimus but its greater in cyclosporine 
A than in tacrolimus the mechanism related to cyclosporine alteration of lipids is through its direct effect on cell membrane 
cholesterol concentration and regulatory pools ,resulting in both increased  synthesis of cholesterol and decreased clearance of 
LDL, HDL levels are typically normal or elevated in the obesity ; however cardio protective HDL fraction may remain low 28, 
29, 30.  
The total blood cell counts were similar in the two study groups, and this is in agreement with another studies that assessed 
cyclosporine A and corticosteroids have no suppressor effects on bone marrow cells, also mycophenolate mofetil usually do 
not cause bone marrow suppression31, even if another study found that prednisone inhibited the expression of 
polymorphoneutriphils to the tissue .This lead in turn to their accumulation in the peripheral blood 32. Even sever anemia is 
appeared due to selective depression of erythropoiesis by immunosuppressive drugs33, anemia resolved when tacrolimus was 
replaced with cyclosporine , more generalized bone marrow suppression has also been reported 34, this result was shown a 
significant difference between the two groups , although hemoglobin was within normal range ,as the excellent graft function 
is achieved ,a burst of erythropoietin secretion is normally followed by effective production of erythrocytes35 . There was a 
significant difference in platelets between the two groups, it seems to be thrombocytosis in cyclosporine group, but this is not a 
greeted with a report said that thrombocytopenia is associated with cyclosporine therapy36. 
There was a significant presence of gingival hyperplasia or gum hyperplasia in cyclosporine group while not in tacrolimus 
group. These findings are consistent with the results obtained from other studies which reported that cyclosporine is well 
known to be associated with the development of gingival overgrowth37 ,the reason for the localization of this effect to the 
gingival is unknown , its possible that the gingival tissue is exposed to higher concentrations of drug than other tissues , and 
this is substantial evidence that the drug acts on the growth and function of both gingival fibroblast and gingival epithelial cells 
via cytokines and growth factors 38. CsA may also cause gingival hyperplasiaby increasing the number of fibroblasts and the 
production of collagen by them 39. 
It was shown that hairtusim is significantly incidence in cyclosporine group while hair loss significantly found in tacrolimus 
group, and these were supported by another study that reported hairtusim found in cyclosporine 40  and hair loss in 
tacrolimus41.  CsA may cause hypertrichosis on the face, arms, shoulders, and back, and is particularly troublesome in young 
women and children, particularly if dark-haired. This disorder is dose-dependent, and, at least in experimental animals, seems 
to be related to the inhibition of NFAT in follicular keratinocytes 42.  
A significant difference in herpes zoster and Kaposi sarcoma and dysmorphic changes that were found more in cyclosporine in 
the current study. This is in concordance with the results obtained by another worker who found that the herpes zoster 
develops in approximately 10% of adult renal transplant recipients and may involve two to three adjoining dermatomes; 
infection is usually caused by reactivation of latent diseases. Post transplanted infection can be primary or transmitted from the 
donor kidney and is associated with Kaposi sarcoma occurring a median of 30 months post transplant, diagnosis is supported 
by pathology and by the presence of human herpes viruses43 . 
There was no significant difference in hypertension as a complicated disease' between cyclosporine and tacrolimus groups and 
this is supported by other studies reported that hypertension is a common after transplantation and may be caused by the effect 
of cyclosporine or tacrolimus 44, Cyclosporine may cause renal vasoconstriction through several mechanisms 45. As a 
 
 
consequence, there is a reduction of glomerular filtration rate and of renal blood flow 46 . In turn, these functional 
abnormalities lead to retention of salt and water, to an increase in extracellular fluids, and to an increased cardiac output47. The 
apparently normal production of renin by the allograft and by the native kidney is inappropriately elevated in a setting 
characterized by extracellular fluid expansion, collaborating with hypertension 48. Tacrolimus also produces clinical post-
transplant hypertension via mechanisms similar to those of cyclosporine 49 although hypertension is less common in patients 
given tacrolimus than in those receiving cyclosporine 50.  There is a significant difference in obesity in the two study groups, it 
was clearly obvious in cyclosporine group due to high appetite in these patients and this is associated with steroid therapy that 
potentate in combination with cyclosporine 51. 
CONCLUSION  
This study found that a tacrolimus-based treatment was significantly better than an immunosuppressive regimen based on 
cyclosporine due to the generally less side effects associated with tacrolimus, despite its effect on increasing diabetes among 
kidney transplant patients. We also hope to conduct more studies to prevent widespread renal failure by knowing the factors 
predisposing to kidney failure and researching factors that can affect medical compliance after kidney transplantation in 
Yemen. 
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Table 1: The patient characteristics : 
 
 
Character 
Cyclosporine 
 
group 
Tacrolimus 
 
group 
 
Total 
No % No % No % 
Sex: 
Male 39 78 20 40 59 59 
Female 11 22 30 60 41 41 
Total 50 100 50 100 100 100 
Age group: 
< 15 years 0 0 1 2 1 1 
15-25 years 15 30 18 36 33 33 
26-35 years 16 32 17 34 33 33 
36-45 years 11 22 10 20 21 21 
>45 years 8 16 4 8 12 12 
Total 50 100 50 100 100 100 
 
Table 2: The original causes of renal failure among our study group : 
 
 
Character 
Cyclosporine 
group 
Tacrolimus 
group 
Total 
No % No % No % 
Hypertension 21 42 16 32 37 37 
Kidney atrophy 7 14 7 14 14 14 
Recurrent UTI 6 12 8 16 14 14 
Obstructive Nephropathy 4 8 6 12 10 10 
Hereditary 2 4 2 4 4 4 
Antibiotic abuse 1 2 3 6 4 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: The main effects of Cyclosporine and Tacrolimus in biochemical functions in a hundred 
renal recipients (Mean± S.D): 
Character (normal 
range) 
Cyclosporine 
group=50 
Tacrolimus 
group=50 P 
Sugar 
(3.05-6.38mmol/L) 5.39±1.67 5.6±2.1 0.581 
Urea 
(1.5-8.3 mmol/L) 6.18±2.1 7.99±8.3 0.143 
Creatinine 
(55-124 mmol/L) 113±32.5 116±74.4 0.761 
T-bil 
(up to 18mmol/L) 14.8±7.8 9.4±5.7 <.0001* 
D-bil 
(up to 5.1 mmol/L) 4.8±2.7 2.2±1.6 <.0001* 
Got 
( up to 35U/L) 25.3±25.1 23.2±24.5 0.686 
Gpt 
(up to 40 U/L) 35.3±46.4 24.9±17.1 0.139 
Alk 
(35-129U/L) 112.5±45.9 98.4±42 0.112 
GGT 
(5-61U/L) 59.8±72.2 29.1±11.4 0.004* 
Diabetes mellitus 2 4 1 2 3 3 
Unknown 7 14 7 14 14 14 
Total 50 100 50 100 100 100 
Table 3: The drug monitoring levels during this study: 
 
Character 
Cyclosporine group Tacrolimus group Total P  
No % No % No %  
Decrease 0 0 1 2 1 1  
 
0.16 Normal 31 62 32 64 63 63 
Increase 19 38 17 34 36 36 
Total 50 100 50 100 100 100 
 
 
CHOL 
(up to 200 mg/dl) 209.2±47.4 144.1±39.8 <.0001* 
HDL 
(>35 mg/dl) 42.3±12.0 34.7±5.2 <.0001* 
LDL 
(<150 mg/dl) 128.3±36.7 81.8±31.5 <.0001* 
TG 
(up to 200 mg/dl) 235.3±109.8 157.8±60.4 <.0001* 
* significant 
Table 5: The main effects of Cyclosporine and Tacrolimus in complete blood count "CBC" in a 
hundred renal recipients 
(Mean+ S.D): 
Character 
(normal range) 
Cyclosporine 
group =50 
Tacrolimus 
group =50 P 
Hb 
(115-180 g/l) 
145.8±17.6 144.1±39.8 <.0001* 
WBC 
(4-10×109cell/L ) 
8.3±2.6 8.3±2.6 0.998 
Plts 
(150-400×109cell/L) 
267.5±71.1 238.9±50.4 .023* 
 
 
 
 
 
 
 
Table 6: The complications of Cyclosporine group and Tacrolimus group in a hundred renal allograft 
recipients: 
Character 
Cyclosporine group Tacrolimus group 
P  
No % No % 
Gum hyperplasia 8 16 0 0 0.003* 
Hairtusim 32 64 2 4 <.001* 
Being diabetic 1 2 10 20 0.004* 
Herpes zoster 5 10 0 0 0.001* 
GITI 7 14 12 24 0.2 
UTI 4 8 5 10 0.7 
Couching face 11 22 0 0 <.001* 
Fatigue 9 18 11 22 0.6 
 
 
 Kaposi sarcoma 1 2 0 0 0.15 
Hair loss 0 0 10 20 0.001* 
Polycythemia 0 0 1 2 0.3 
Gastritis 2 4 5 10 0.23 
Obesity 27 54 14 28 <.001* 
Hypertension 12 24 5 10 0.09 
Herpes simplex 14 28 3 6 0.003 
No complication 6 12 4 8 0.5 
